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Editor,
To achieve extended anaesthesia and analgesia, a psoas
compartment–sciatic nerve block (PCSNB) requires
administration of large volumes of potentially cardiotoxic
local anaesthetics. Due to the anatomic location of the
lumbar plexus [1], mostly within muscle tissue, initial
absorption of the administered local anaesthetics after a
psoas compartment block could result in relatively high
early plasma concentrations. This phenomenon theoreti-
cally enhances the risk of local anaesthetic toxicity of this
anaesthetic technique.
The primary aim of this study was to analyse total plasma
concentrations after administration of the maximum
recommended doses of bupivacaine, levobupivacaine
and ropivacaine in a PCSNB and to compare these data
with described ‘threshold plasma concentration values’
producing local anaesthetic toxicity. The second aim was
to require more insight into pharmacokinetic profiles of
used local anaesthetic administered in a PCSNB. Both
aims should lead to a better understanding of the safety
assessment of a PCSNB.
The present study was approved by the Medical Ethics
Review Committee of the VU University Medical
Centre. Patients participating in a randomized con-
trolled trial [2], comparing the clinical efficacy of
PCSNB using levobupivacaine, ropivacaine and bupi-
vacaine, with ASA status I–III, age above 18 and
scheduled for total hip replacement under general
anaesthesia, were included in this study. Exclusion
criteria were patients’ refusal, coagulation disorders,
infections at the puncture site, known allergy to local
anaesthetics and preexisting neurological disorders.
Patient information was given at the preoperativeright © European Society of Anaesthesiology. Un
0265-0215  2009 Copyright European Society of Anaesthesiologyscreening clinic and written informed consent was
obtained one day prior to surgery.
Patients were randomly allocated to receive a combined
PCSNB with one of three local anaesthetics: 50 ml bupi-
vacaine 0.3% (group BUPI), 50 ml levobupivacaine 0.3%
(group LEVO) or 50 ml ropivacaine 0.45% (group ROPI),
which are maximal recommended doses (manufacturer’s
indication) for a single injection peripheral nerve block-
ade (PNB). Patients were assigned to the treatment
modalities using a block-wise randomization procedure
in blocks of three. Epinephrine 1 : 200.000 (5mg ml1)
was added to all solutions. After induction of general
anaesthesia, PCSNB was performed according to the
landmarks described by Labat [3] and Chayen et al.
[4], with the aid of a nerve stimulator and special coated,
short-beveled, stimulating needles (Stimuplex HNS 11,
needle 150 mm/20G, Braun Medical, Melsungen,
Germany). Ten millilitre of local anaesthetic solution
was administered to the sciatic nerve and 40 ml was
injected incrementally with gentle aspiration into the
psoas compartment. The time at which all of the local
anaesthetic solution had been injected was taken as time
zero. Arterial plasma samples for local anaesthetic total
plasma concentration analysis were taken (via radial
artery catheter) before block (reference) and at 2, 5,
10, 30, 60, 90, 120, 180 and 240 min after PCSNB. Serum
concentrations of bupivacaine, levobupivacaine and ropi-
vacaine were determined by high-performance liquid
chromatography with ultraviolet detection (HPLC-UV)
after liquid–liquid extraction. Cmax (maximum plasma
concentration), Tmax (time to reach Cmax) and area under
the curve (AUC, total absorption of local anaesthetics)
were determined. The AUC was calculated for T0–240 min
using the trapezium rule. Based on standard power
calculation of the clinical efficacy study [2], 15 patients
were needed per group. Differences between different
local anaesthetics with respect to pharmacokinetic
indices were analysed using the Kruskal–Wallis and
the Mann–Whitney U-tests. Relationships between Cmax
and age, length, weight and BMI of the patient were
assessed by the Spearman’s r correlation coefficient, and
the Mann–Whitney U-test was used to assess sex-related
differences in Cmax. For all analyses, an a value less than
0.05 was considered statistically significant.
Forty-five patients were included in the study, equally
divided over the three intervention groups. All patients
completed the trial. There were no differences between
groups concerning patients’ characteristics (Table 1).
PCSNBs were all technically successful and time
between sciatic nerve and psoas compartment blocksauthorized reproduction of this article is prohibited.
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Table 1 Patients’ characteristics
Groups BUPI (n¼15) LEVO (n¼15) ROPI (n¼15)
Age (years)a 69.4 (12.8) 60.6 (16.7) 69.1 (10.7)
Height (cm)a 167.7 (8.5) 167.8 (9.7) 163.2 (10.3)
Weight (kg)a 72.8 (14.1) 71.4 (15.5) 71.5 (14.5)
Male/Female 3/12 4/11 3/12
Duration of surgery (min)a 96 (21.9) 102 (21.6) 94 (20.2)
BUPI, bupivacaine; LEVO, levobupivacaine; ROPI, ropivacaine. a Data in means
(SD).
Fig. 1
Total plasma concentrations of bupivacaine, levobupivacaine and
ropivacaine after psoas compartment–sciatic nerve block. Values in
median [interquartile range (IQR)].was less than 7 min. Total plasma concentration data
of one patient within the bupivacaine group were
excluded because there was an unexplained, pharmaco-
logically impossible variation in different plasma concen-
tration values measured at different time frames
(t¼ 0 min: 0.0mg ml1, t¼ 2 min: 12.5mg ml1, t¼ 5 min:
min: 0.26mg ml ). There was no correlation between Cmax
values and sex, age, length, bodyweight and BMI.
Total plasma concentrations of ropivacaine (Cmax) were
higher than bupivacine and significantly higher than
levobupivacaine (Mann–Whitney U-test; P¼ 0.036)
(Fig. 1). The variance of all plasma concentrations was
large, regardless of which local anaesthetic was used. A
notable observation is a second small increase in local
anaesthetic total plasma concentration after 90–110 min
postpuncture in all three groups.
Systemic absorption of ropivacaine (AUC0–240) is signifi-
cantly higher than bupivacaine or levobupivacaine (Krus-
kal–Wallis; P< 0.001; see Table 2).
Figure 2 displays scatter plots of Cmax versus Tmax.
Lowest individual peak plasma concentration values
were measured for levobupivacaine compared with bupi-
vacaine and ropivacaine [NB: overall median Cmax values
(Table 2) were lowest for bupivacaine] and the Tmax was
longer for levobupivacaine compared with the other two
local anaesthetics. Three patients within the ropivacaine
group and one patient within the bupivacaine group
showed large plasma concentrations (ropivacaine: 2.36,
2.76 and 3.06mg ml1; bupivacaine: 3.24mg ml1).
Neither patient-related factors (age, weight, length)
nor procedure-related factors (no blood aspiration prior
injection or difficult procedure) were correlated with
these relatively large plasma concentrations.
In this study, measured local anaesthetic total plasma
concentrations after a PCSNB, with given dosages ofight © European Society of Anaesthesiology. Una
Table 2 Pharmacokinetics data
Dose (mg) Cmax (mg l
1)a
Bupivacaine 150 0.47 (0.34–1.07)
Levobupivacaine 150 0.64 (0.46–0.90)
Ropivacaine 225 0.90 (0.74–1.19)
Reason for describing median Cmax and Tmax with interquartile range (IQR), instead of m
the curve. a Values are medians (IQR 25–75%). b Values are meanSD.bupivacaine, levobupivacaine or ropivacaine, remained
far below described threshold values to produce central
nervous system (CNS) or cardiac toxicity [5]. Probably
today’s dose recommendations provided by pharmaceu-
tical companies may be conservative and the margin of
safety is probably much wider than assumed.
The low local anaesthetic total plasma concentrations we
found were comparable with those found in other studies
concerning local anaesthetic plasma concentrations after
lower extremity peripheral nerve blocks [6,7]. Recently,
Vanterpool et al. [6] described a mean maximum total
plasma concentration of 1.56 mg l1 ropivacaine after a
PCSNB with 300 mg ropivacaine. Higher values of their
measured plasma concentrations could be explained by
a higher ropivacaine dose and a lower ratio of added
epinephrine.
A notable observation was a large interpatient variability
in local anaesthetic plasma concentrations. This could be
the result of the anatomical variation in the ‘psoas com-
partment’ [1]. Injecting local anaesthetic within highly
vascularized muscle tissue could lead to higher local
anaesthetic plasma concentrations than injecting local
anaesthetic in a plexus sheath between different muscles.
For unknown reasons, we only found high local anaes-
thetic plasma concentrations in one patient in the bupi-
vacaine group and three patients in the ropivacaine
group, suggesting very high initial absorption of the localuthorized reproduction of this article is prohibited.
Tmax (min)
a AUC0–240 min (mg h l
1)b
4.8 (1.8–29.8) 1.660.95
30.2 (5.2–60.0) 1.690.53
5 (5.0–10.0) 3.341.23
ean values, is the fact that given data are not normally distributed. AUC, area under
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Fig. 2
Scatter plots of maximum local anaesthetic concentration (Cmax) by
maximum time (Tmax) following a single injection of 150 mg (levo)
bupivacaine or 225 mg ropivacaine. Each symbol represents one
patient. Some symbols are time-shifted by 1 min in order to improve
readability of figure. Values in median [interquartile range (IQR)].anaesthetics administrated in muscle tissue. Partial intra-
vasal injection of local anaesthetics is less likely due to
the absence of tachycardia and hypertension during
injection (epinephrine was added as an ‘intravascular
marker’) but could not be ruled out.
The higher maximal plasma concentration of ropivacaine
compared with levobupivacaine is probably due to a
higher dosage of ropivacaine (225 versus 150 mg).
Although the AUC0–240 min of bupivacaine and levobu-
pivacaine were equal, there was a trend towards levobu-
pivacaine having a longerTmax compared with bupivacaine
(see Fig. 2). Probably, initially systemic absorption of
levobupivacaine is slower than bupivacaine and could
be explained by a more vasoconstrictor effect of levo-
bupivacaine compared with racemic bupivacaine as
described by Aps and Reynolds [8]. This difference
was not statistically significant and further studies are
needed to analyse this phenomenon.
A notable observation was a second, small, increase in
plasma concentration, within all three groups after
t¼ 90 min. Planned awakening at that moment from
general anaesthesia, which led to a higher heart rate,
blood pressure and cardiac output, resulting in a better
perfusion of muscles around the psoas compartment
could be the reason for this second elevation in the
plasma concentrations curve. Further studies are needed
to analyse the influence of cardiac output dynamics on
systemic absorption of local anaesthetics.
A minor shortcoming of the present study is that only
local anaesthetic total plasma concentrations were
measured. The unbound local anaesthetic concen-
trations, which might be more closely associated withright © European Society of Anaesthesiology. Untoxicity reactions, and a(1)-acid glycoprotein were not
measured. Because the unbound fraction has a similar
proportional plasma concentration curve and the fact
that surgery results in a rise of a(1)-acid glycoprotein
(decreasing the unbound fraction) make total local
anaesthetic plasma concentration data still valuable for
safety assessment.
In conclusion, total plasma concentrations of the maxi-
mum recommended doses of bupivacaine, ropivacaine
and levobupivacaine used in a PCSNB remain far below
the described toxicity thresholds and make the margin of
safety probably much wider than current standards,
allowing the usage of a higher dose than that recom-
mended by the manufacturer. However, one should be
cautious about using high doses of potentially cardiotoxic
local anaesthetics in a PCSNB because the anatomic
location of the lumbosacral plexus makes high initial
systemic absorption possible. Finally, although not stat-
istically significant, levobupivacaine seems to have a
slower initial systemic absorption, which could make this
local anaesthetic more favourable when using large
dosages of local anaesthetics in a PCSNB. Further studies
are needed to investigate this phenomenon.
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During thoracic anaesthesia and in postoperative care, it
is necessary to monitor haemodynamic status, especially
in high-risk patients. Although the Swan–Ganz catheter
is considered the gold standard advanced haemodynamic
monitor, right now there is no consensus on the optimal
haemodynamic monitoring method in thoracic anaesthe-
sia for high-risk patients. We intend to present a method
[the pulse contour cardiac output–volumetric ejection
fraction monitoring system (PiCCO–VoLEF); Pulsion
Medical Systems, Munich, Germany], which we used
during thoracic anaesthesia for a patient who was to
undergo heart transplantation.
A 45-year-old woman, a candidate for heart transplan-
tation, had had previous history of hypertension, insulin-
dependent diabetes mellitus (IDDM) and myocardial
infarction and had undergone three-vessel coronary
artery stenting as well as implantable cardioverter defi-
brillator (ICD) implantation. During her preoperative
evaluation for heart transplantation, a tumour, 19 mm
in diameter, was found in her right lung. Subsequently,
a thoracoscopic partial lung resection was planned in
order to verify the nature of the tumour.
Perioperative assessment and preparation
From among the preoperative evaluation results, we
intend to highlight the results of echocardiography, exer-
cise test and invasive haemodynamical measurement.
Echocardiography revealed a second to third degree
mitral insufficiency and tricuspidal insufficiency, dilated
left ventricle and atrium, diffuse hypokinesis and akine-
sis, a 60 mmHg right ventricular systolic pressure and a
15% ejection fraction. In dobutamine stress echocardio-
graphy combined with the Swan–Ganz catheter, no
viability was seen at the myocardium after stent implan-
tation, but chronotropic incompetence and improvement
in the heart function were present.
The day before surgery, a VoLEF pulmonary catheter
(PV2047, VoLEF Catheter PACC 947, Pulsion Medical
Systems) was inserted via the right internal jugular vein
into the right pulmonary artery under the guidance of
flouroscopy. Because the VoLEF pulmonary catheter has
no shield, of its own, we used the standard pulmonary
artery catheter shield (Catheter Contamination Shield
80 cm, Edwards Lifesciences, Irvine, California, USA).
After catheter fixation, we inserted a PiCCO catheter
(PV2015L20A, Pulsiocath; Pulsion Medical Systems) into
the right femoral artery and performed the baselineight © European Society of Anaesthesiology. Unameasurements. For haemodynamic monitoring, we used
a combination of PiCCO Plus V 5.2.2 and VoLEF V 1.0
(Pulsion Medical System) monitors.
Intraoperative phase
On the morning of the surgery, we switched the ICD to
pacemaker mode via telemetry.
At the time of skin incision, one-lung ventilation (OLV)
was started with a fiO2 of 100%. The surgical plan was
originally a video-assisted thoracoscopic surgery (VATS),
but due to adhesions caused by previous pneumonias,
intraoperatively, an open thoracotomy was decided. At
15 min of OLV, the pulmonary vascular resistance (PVR)
increased, tachycardia and then bradycardia developed,
and then the SatO2, pulmonary artery pressure (PAP)
and cardiac output (CO) decreased and central venous
pressure (CVP) increased. We immediately started and
continued double-lung ventilation until the end of sur-
gery and the administration of dobutamine, norepi-
nephrine and the infusion rate was increased. The above
parameters were normalized in a few minutes. The
remaining part of the surgery was uneventful and we
were able to decrease the dose of dobutamine and nor-
epinephrine. The surgeons performed the resection of
the eighth segment of the right lung. After completion of
the surgery, we changed the double-lumen tube (DLT)
to a single-lumen tube and transported the patient to the
ICU under sedation and mechanical ventilation.
In the ICU, we omitted norepinephrine and gradually
decreased the dose of dobutamine. In the sixth post-
operative hour, we could extubate the patient and
switched the ICD on. On the third postoperative day,
we omitted dobutamine and on the fourth day, we
removed the haemodynamic catheters and the chest
tubes; the patient was admitted to the ward and on the
tenth postoperative day, the patient left the hospital. The
results of haemodynamic monitoring during the perio-
perative period are shown in Fig. 1.
We were facing hard pathophysiological conditions and
we chose a monitor that enabled us to meet the monitor-
ing requirements. The underlying conditions that we had
to face were as follows:(1) Lutheft and right heart failure and dilation, tricuspidal and
mitral regurgitation, elevated right ventricular and
pulmonary arterial pressure, ICD in situ: as mitral and
tricuspidal regurgitation caused dilated pulmonary
vessels, we found the wedge-position very peripheral
(60 cm). Additionally, we had to avoid knotting of the
long pulmonary catheter and the ICD electrode inside
the heart during insertion. Fortunately, the VoLEF
pulmonary catheter is radiopaque and 110 cm long,
so under fluoroscopic guidance, the positioning of the
catheter to the correct place became possible.orized reproduction of this article is prohibited.
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Fig. 1
Results of haemodynamic measurements in the perioperative period. GEF, global ejection fraction; PAP, pulmonary artery pressure; PVRI, pulmonary
vascular resistance index; RVEF, right ventricular ejection fraction.(2) Hrighypoxic pulmonary vasoconstriction: if alveolar
oxygen tension falls below 60 mmHg, hypoxic
pulmonary vasoconstriction occurs. This vasocon-
striction is a significant afterload for the right
ventricle, especially if it is impaired. An acute
elevation of the afterload causes a dilatation of the
impaired right ventricle and the interventricular
septum is shifted towards the left ventricle, resulting
in a decrease in the diastolic filling of the left
ventricle. This decreased left ventricular filling leads
to a decrease in CO and a consequent collapse of the
circulation. The PiCCO–VoLEF monitor enabled us
to measure PVR, right ventricular ejection fraction
(RVEF), the ratio of the right and left heart (R/L), the
right heart and left heart end-diastolic volume
(RHEDV, LHEDV) and PAP. With the help of this
monitor, the diagnosis and the immediate treatment
of the left and right heart failure became possible.
One of the most important parameters of systemic
circulation for us was systemic vascular resistance
(SVR), because the patient had mitral insufficiency in
her previous history and we had to secure optimal
vascular resistance both because of the left ventricle
and because of the previous mitral insufficiency. In
order to decrease PAP, we used dobutamine and we
compensated for its systemic vasodilatory effect with
norepinephrine. Optimization of SVR increased the
left ventricular filling, because it pushed the
interventricular septum back towards the right
ventricle. In contrast to this, an elevated SVR wouldt © European Society of Anaesthesiology. Unauincrease the regurgitant blood volume to the left
atrium and would decrease CO [1–6].(3) Increased blood flow in the lung (fluid overload): after
pulmonary resection, sometimes acute lung injury
(ALI) and pulmonary oedema may occur. The origin of
this oedema is complex and not entirely clear: surgical
manipulation, fluid overload, damage to the alveolar-
capillary barrier from mechanical ventilation and the
reexpansion of the lung are all implicated. With the use
of the PiCCO–VoLEF monitor, one can identify the
pulmonary oedema by measuring extravascular lung
water (EVLW). The use of this monitoring technique
helps todifferentiatebetweentheoedemasofdifferent
origins; if the pulmonary vascular permeability index
(PVPI) is below 3, the oedema is most probably
of cardiac or hydrostatic originand if the PVPI is greater
than 3, the origin of the oedema is postresectional
ALI/adult respiratory distress syndrome (ARDS). The
use of this monitoring technique also enables us to
guide fluid therapy according to needs [7,8].During thoracic anaesthesia for high-risk patients, the
anaesthesiologist has to know the pressure of the pul-
monary vascular system, the left/right and global heart
functions and the EVLW/PVPI. These parameters can be
measured separately with pulmonary artery catheter and
a PiCCO monitor, but the combined use of the PiCCO–
VoLEF monitor makes it possible for the anaesthesiol-
ogist to use only one system.thorized reproduction of this article is prohibited.
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Editor,Table 1 Countries of practice and number of respondents
Country and number of respondents (N)
Argentina 8 Indonesia 1 Romania 1
Austria 3 Iran 1 Russia 3
Australia 2 Israel 1 Serbia 2
Belgium 1 Italy 7 Slovakia 1
Bulgaria 1 Japan 1 Slovenia 1
Croatia 3 Jordan 1 Spain 6
Czech 1 Kazakhstan 1 Sweden 2
Denmark 2 Korea (N) 1 Switzerland 6
Finland 1 Latvia 1 Turkey 2
France 4 New Zealand 1 UK 12
Germany 10 Poland 3 USA 3
Holland 8 Portugal 1At the age of 165 nitrous oxide is twice as old as the oldest
practising anaesthetist! As an anaesthetic agent it has had
better success at weathering critical reviews and standing
the test of time than any other agent. It has been
suggested that it owes this success to the fact that it is
a weak anaesthetic/analgesic agent with mild adverse
effects during an average time use. However, recent
research suggests that there are serious adverse events
that occur postoperatively due to nitrous oxide. These
morbidities are either inadvertently attributed to other
causes or the link to the real culprit, nitrous oxide, is
nebulous and blurred. The most obvious distressing side
effect, but which is not directly fatal, is postoperative
nausea and vomiting (PONV). Several trials have shown a
significant reduction in PONV by omitting nitrous oxide
[1]. The other side effects are long-term and are either
due to recreational abuse or prolonged exposure [2]. As a
result there is no universality in the use of nitrous oxide as
a routine anaesthetic agent, with some practitioners call-
ing for an all out ban on its use. This survey was carried
out to assess which way the pendulum is swinging regard-
ing the use of nitrous oxide.ight © European Society of Anaesthesiology. UnaMethod
An electronic questionnaire was sent to members of the
European Society of Anaesthesiology (ESA) through the
ESA Secretariat. Responding members sent their com-
pleted questionnaires directly to the author by E-mail.
Results
A total of 123 questionnaires were returned from all over
the world, with the majority of the responses coming from
Europe (Table 1). The majority (86.1%) of respondents
were specialist anaesthesiologists or consultants. Out of
the total 64.3% admitted to using nitrous oxide in their
clinical practice. Approximately 29% of the nitrous oxide
users always use it for general anaesthesia without excep-
tion. The cases in which nitrous oxide is used included
in-patients, day surgery and paediatric patients. The
majority (71%) of nitrous oxide users would not use it in
some cases. Only 33% (41) of the total respondents never at
all use nitrous oxide in their practice. Air is used by the
majority (73.2%) of anaesthesiologists as an alternative to
nitrous oxide. Xenon is still not widely used (1.6%). Of the
respondents from the UK 92% use nitrous oxide compared
with 50% in Holland, 50% in Spain and 30% in Germany.
On the prediction of the future use of nitrous oxide, 53%
believe nitrous oxide will disappear from routine clinical
use. Reasons expressed by proponents for the use and for
nonuse of nitrous oxide range from clinical to environ-
mental issues. Proponents for nitrous oxide use empha-
sized time-tested safety record, low cost anaesthesia
and convenience. On the contrary nonusers highlighted
PONV, the emerging myocardial adverse effects, and more
importantly the fatalities that ensue when human error
comes into play, something that would never happen with
use of air. Table 2 shows commonly cited reasons for and
against use of nitrous oxide.
Discussion
The survey clearly shows that nitrous oxide is still pretty
much in vogue with the current generation of anaesthe-
siologists notwithstanding the piling evidence against it.
The majority of the respondents (64.3%) use nitrous
oxide in their anaesthetic practice, with a minority
(33.3%) never at all using it. A similar survey 7 yearsuthorized reproduction of this article is prohibited.
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Table 2 Reasons given for and against using nitrous oxide
For Against
Analgesia (obstetric and perioperative) Significant side effects (PONV, myocardial depression, expansion of
gas filled cavities, anaemia)
Anaesthesia (augments, good for high risk of awareness patients,
spares volatile, quick onset/offset, good for paediatric cases, low cost agent)
Harm much greater than usefulness
Traditional, acceptable practice Unnecessary, better alternatives available
Cheap, well tolerated, convenient Low anaesthetic and analgesic potency
Useful in certain procedures (retinal detachment, tympanoplasty) Environmental pollutant and greenhouse effect
Mild side effects compared with other agents Possible teratogenicity (pregnant staff)
Mistakes may be fatalago showed that 95% of UK anaesthetists used nitrous
oxide (frequently or occasionally), with a tiny minority
(5%) never using it [3]. These results, albeit from a small
sample, show that in the UK there has not been any
change in the usage of nitrous oxide since the Henderson
et al. [3] survey in 2002. However, in Europe the drive to
remove nitrous oxide from routine practice seems to be
moving faster than in the UK. Some of the European
respondents reported that nitrous oxide has been banned
and is no longer available in their hospitals.
Biochemically nitrous oxide inhibits methionine synthase,
an essential ubiquitous cytosolic enzyme, by oxidizing the
cobalt ion in cobalamin (vitamin B12) from Coþ to Co3þ.
This results in failure to generate the intermediary methyl
donor, S-adenosylmethionine, key to the synthesis of
DNA, RNA, myelin, catecholamines and other substances
requiring the methylation process. Folate is an intermedi-
ary in the methylation process and is essential in the
biosynthesis of purines, pyrimidines, serine and glycine.
Homocysteine levels rise due to the blockade of meth-
ionine synthase. Homocysteine has been shown to cause
endothelial dysfunction and increased tendency to coagu-
lation. The biosynthetic dysfunction caused by nitrous
oxide provides the link to the feared teratogenic, subacute
combined neurodegeneration of the cord, haematological
toxicity, immune dysfunction, and myocardial ischaemic
complications of nitrous oxide [4].
Except in cases of abuse, the nationally set occupational
exposure limits (OEL) guarantee minimal safe exposure
in clinical practice. However, this does not apply to the
patient whose exposure is time-dependent. Methionine
synthase activity approaches zero after about 200 min of
exposure to nitrous oxide in mice [5]. For the average
clinical exposure of about 1.5 h there is a 50% reduction in
methionine synthase activity and takes 3–4 days to fully
recover. Although the ENIGMA I trial [1] demonstrated
a reduction in major complications with avoidance of
nitrous oxide, it has been suggested that it was probable
that the use of high oxygen (80%) was the reason rather
than omission of nitrous oxide. That fact was confirmed
earlier by Fleischmann et al. [4], who found no statisti-
cally significant difference in the rate of infection and
other secondary outcomes between use of nitrous oxide
and nitrogen. The ENIGMA I group has since embarkedright © European Society of Anaesthesiology. Unon ENIGMA II, which might shed more light on the
clinical adverse effects, if any, of nitrous oxide, particu-
larly the endothelial dysfunction related to perioperative
high levels of homocysteine [6,7].
The use of anaesthetic machines without antihypoxia
devices or some other mishap in which nitrous oxide is
delivered without oxygen have resulted in fatalities. Such
accidents do not occur when air is substituted for nitrous
oxide. It can be argued that, except for these cases of
human error, nitrous oxide has been successfully used in
clinical practice without major problems for more than
one and half centuries. Use of nitrous oxide more than
doubles the incidence of postoperative nausea and vomit-
ing [1]. This is the most quoted reason in the survey for
abandoning use of nitrous oxide. A real threat to nitrous
oxide, however, is posed by its being the third most
climatologically significant greenhouse gas after carbon
dioxide and methane [8]. With a 120 year long atmospheric
lifetime and 300 times the global warming potential of
carbon dioxide, nitrous oxide is likely to be banned from
use unless ways are found to prevent atmospheric pollu-
tion. Most of the atmospheric nitrous oxide (99%), how-
ever, originates from agricultural and industrial sources,
with probably about 0.05% coming from medical and
dental use. The impact of eliminating medical and dental
nitrous oxide contributions on the greenhouse effect is not
known, but it is thought it would be negligible.
The limitation of the survey is that it was small, and, like
any survey, may suffer from response bias. However, this
was an international survey and therefore probably pro-
vides a global opinion on the use of nitrous oxide.
Conclusion
Nitrous oxide occupies such a unique niche that no other
agent has managed to dislodge it for more than one and
half centuries. Although there is a trend towards reducing
use of nitrous oxide, it is quite probable that this agent
will outlive any currently practising anaesthesiologist.
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Editor,
With the incidence of obesity increasing in the UK,
difficult mask ventilation with increasing BMI is well
documented. The laryngeal mask airway (LMA) is an
established adjunct for use when difficulty is encoun-
tered with mask ventilation. We describe a case of a
morbidly obese female patient which deteriorated into a
can’t intubate, can’t ventilate (CICV) scenario and how
the situation was salvaged using a paediatric-sized LMA
when other recognized techniques had failed. This is the
first documented case of a paediatric-sized LMA being
used as a rescue technique in an adult CICV scenario.
Case report
A 51-year-old female patient, known to be a Lehane and
Cormack grade 4 laryngoscopy, presented for elective
revision of a left total elbow replacement. At 110 kg, she
had a BMI of 50. Apart from juvenile arthritis, her past
medical history was unremarkable and she denied symp-
toms of obstructive sleep apnoea. Examination revealed a
morbidly obese female patient with mouth opening of
two fingers due to temporomandibular joint involvement
and a Mallampati grade 4 view. She had a receding
mandible and limited neck extension. The cricothyroid
membrane was not palpable. Other examination andight © European Society of Anaesthesiology. Unainvestigations were normal. For the original operation
2 years previously, the anaesthetist had abandoned an
awake fibre-optic intubation (FOI) due to the patient
being unable to tolerate it. Anaesthesia was achieved at
that time using a gas induction, with mask ventilation
made possible using a two-person technique. Intubation
was ultimately performed fibre optically using a size 3
LMA. Extubation and the postoperative period had been
uneventful. Over the intervening 2 years, the patient had
gained 20 kg. A combined regional and general anaes-
thesia approach was planned. However, after her previous
experience, despite counselling, the patient refused to
undergo an awake FOI. Therefore, the initial plan was to
induce anaesthesia while maintaining spontaneous venti-
lation and to perform an oral FOI using a Berman airway
(Vital Signs, Littlehampton, UK). The back-up plan was
to wake the patient up. The patient consented, and risks
including hypoxic brain injury and death were discussed.
Two anaesthetists with experience in difficult airway
management were present, and an ear, nose and throat
(ENT) surgeon was immediately available. The patient
was positioned using a ‘ramping’ technique and the
airway topicalized using 4% lidocaine. After preoxygena-
tion, anaesthesia was induced using increments of pro-
pofol followed by a maintenance of sevoflurane in oxygen
to maintain spontaneous ventilation. Oral FOI via the
Berman airway failed due to supraglottic tissue folds
obstructing the view, despite repositioning and resizing
of the Berman airway. During this time, the airway had
become increasingly obstructed despite maximum jaw
thrust and a two-person mask technique. Despite success
at the previous anaesthetic, oropharyngeal, nasopharyn-
geal airways and a size 3 LMA failed to improve the now
impending CICV situation. A size 21/2 classic LMA was
inserted in an attempt to provide better positioning in the
airway with the shorter tube length and smaller mask.
Immediately on insertion, there was resolution of the
clinical signs of obstruction. Anaesthesia was maintained
using sevoflurane, and the size 21/2 LMA was used as a
conduit for a fibre optically placed Aintree intubating
catheter (AIC) (Cook, Letchworth, UK), before removal
of the LMA and railroading of a size 6.5 Fastrach endo-
tracheal tube (Intavent Orthofix, Maidenhead, UK). An
axillary brachial plexus block was performed and the
21/2 h operation proceeded uneventfully. Prior to extuba-
tion, the AIC was reinserted and the patient extubated
in the upright position fully awake. The postoperative
period prior to discharge was uncomplicated.
Discussion
This is the first case in the literature in which a size 21/2
LMA has been used, not only as a rescue technique but
also as a conduit for intubation in the difficult adult
airway. The reason for failing to establish a patent airway
with the size 3 LMA in the same patient in whom
previous use had been successful is unclear. Reasons
often cited for difficulty with LMA insertion and airwayuthorized reproduction of this article is prohibited.
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spasm, lay in a failure to negotiate the back of the tongue,
epiglottic downfolding and overinsertion or underinser-
tion. The size 21/2 LMA itself is shorter at 12.5 cm versus
19 cm with an internal diameter of 8.4 mm versus 10 mm.
However, the likely reason was the size of the mask itself.
It is credible that, in a morbidly obese female patient, the
loss of upper airway tone, in combination with increased
supraglottic folds of tissue, may result in a decreased
space for the mask, thus causing potential folding of
the size 3 tip onto itself and epiglottic downfolding.
Alternatively, the underinsertion of the larger size 3 cuff
may have in fact resulted in the LMA tip impinging on
the arytenoids causing them to infold or for the tip itself
to collide with the laryngeal inlet causing complete
obstruction. The only major change on examination
was the patient’s weight gain with potential changes in
the supraglottic tissues which may have been more suited
to the smaller mask size of the size 21/2 LMA. However,
on searching the literature, there are no data looking
at pharyngeal architecture in patients with increased
BMIs and how this impinges on LMA size. Indeed,
the manufacturers advocate a size 6 LMA for patients
over 100 kg and a size 21/2 for patients of 20–30 kg. With
the increased numbers of morbidly obese patients pre-
senting for surgery and documented difficulty with mask
ventilation, this is an area requiring further study.
Owing to the previous difficulties, an appropriate plan for
this patient would have been to perform an awake FOI. It
is unclear from the records as to why the procedure was
not previously tolerated by the patient but highlights the
importance of appropriate sedation, good topicalization,
and skilled endoscopy. A number of different sedation
techniques and drugs are used individually or in combi-
nation. The merits of propofol versus remifentanil have
been previously discussed [1]. Although propofol has the
benefit of amnesia, particularly of importance in patients
requiring repeated procedures, remifentanil has been
shown to generate better intubating conditions, is more
‘forgiving’ of inadequate topicalization, and advocates
argue that amnesia is less of an issue if the procedure
is done well with no patient distress. The learning curve
for nasal FOI has been quoted as 18 to achieve intubation
in less than 60 s, but the number required to maintain
those skills is unclear [2]. Indeed, awake FOI failure rates
have been previously quoted as 1.5%, and anaesthetists in
the UK in comparison with other countries do not per-
form many awake FOIs, resulting in a rarely practised
skill which is then used in difficult patients [3].
The merits of an inhalational versus intravenous induc-
tion to maintain spontaneous ventilation have been
previously discussed in the literature, and the target-
controlled infusion (TCI) of propofol may have given
more control and perhaps averted the CICV scenario.
However, it is likely that problems with upper airwayright © European Society of Anaesthesiology. Unobstruction would still have remained an issue in trying to
achieve a deep enough plane of anaesthesia for airway
manipulation even in the presence of airway topicaliza-
tion. In addition, difficulties lay in deciding the appro-
priate weight for TCI pump programming.
Case reports of intubation using an AIC loaded on a fibre-
optic scope and using a classic LMA in difficult intuba-
tions have been reported in the literature [4,5]. Indeed,
there are two case series published regarding the use of
the AIC via the classic LMA in adults, but none using a
paediatric-sized LMA in this group [6,7]. This is the first
case in the literature.
Finally, this case highlights several ethical issues and the
importance of communication between the anaesthetist
and the patient after the difficult situation of a previously
failed awake FOI and the importance of informed
consent.
We have described the successful rescue of a morbidly
obese patient in a CICV scenario using a recognized
technique yet in an unconventional way by using a
paediatric-sized LMA in a morbidly obese adult. This
case reiterates the difficulty of mask ventilation, a need
for alternative techniques for airway patency, and further
work required to ascertain the appropriate size of LMA in
this group of patients when difficulty arises.
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Endovascular treatment of arteriovenous malformation
(AVM) with the Onyx Liquid Embolic System (Onyx;
Micro Therapeutics, Inc., Irvine, California, USA) can
achieve a high occlusion rate, enhance the safety of the
operation and improve the clinical prognosis for the
patients compared with other embolic agents [1,2].
The Onyx Liquid Embolic System is a newer embolic
agent that was developed in the early 1990s [1]. Onyx
consists of ethylene vinyl alcohol dissolved in dimethyl
sulphoxide (DMSO) and suspended micronized tantalum
powder to provide contrast for visualization under fluoro-
scopy. In the present review, we report our experience
with desaturation during embolization of AVMs.
Forty-six patients, 26 male and 20 female, 10–73 years of
age (mean age 38.4 16.75), who were treated for AVMs
by an endovascular approach using Onyx over a period of
10 months (January–October 2008) were enrolled in this
study. General anaesthesia was induced with propofol
(2 mg kg1), fentanyl (2mg kg1) and cicatracurium
(0.15 mg kg1) and was maintained with continuous intra-
venous remifentanil and sevoflurane (minimum alveolar
concentration 0.5–0.8) in 50% O2–N2O. Ventilation was
maintained to achieve a PaCO2 of 30–35 mmHg. Heart
rate (HR), intraarterial blood pressure (IBP), oxygen
saturation (SpO2) and end-tidal CO2 (EtCO2) values were
continuously monitored. HR, IBP and SpO2 changes in
response to DMSO and Onyx injection were recorded.
Seventeen of the patients developed desaturation during
the infusion of DMSO; 11 of them demonstrated 3%
desaturation from baseline, and six had severe desatura-
tion (4–8% below baseline). None of these patients had
any cardiological or pulmonary medical history. No sig-
nificant changes in blood pressure (BP), HR or ECG were
observed that could be attributable to DMSO infusion.
The episodes of oxygen desaturation lasted a few min-
utes and the saturation returned to baseline, without any
other clinical concerns during the procedure. Because of
the fact that the desaturation was minimal, arterial blood
gases were not taken. In only one case, in a patient with a
giant AVM, we observed severe desaturation (SpO2 89%)
after recovery from anaesthesia, accompanied by tachyp-
noea. The first arterial blood gases revealed hypoxaemia
( pO2 61.8 mmHg). SpO2 gradually improved to 97%, pO2
returned to normal ( pO2 92.3 mmHg) and the patient
recovered fully 20 min later and was discharged from
the postanaesthesia care unit. There were no other
adverse events related to Onyx or anaesthesia. We saw
no evidence of toxicity or any anaesthetic complicationsight © European Society of Anaesthesiology. Unain our group of patients, our only clinical concern being a
tendency to oxygen desaturation, lasting a few minutes
with no clinical consequence.
The advantage of using Onyx is that it is a radio-opaque
nonadhesive liquid embolic material easily injected
through a microcatheter. It eliminates the risk of gluing
the catheter to the vessel and therefore allows a longer
injection time and a wider range of different injection
rates. The disadvantage of Onyx is that it uses DMSO as a
solvent. DMSO is a hydrogen-bound disrupter, a cell-
differentiating agent and a hydroxyl radical scavenger
and has been used as an anticancer and an analgesic
agent [3]. If given in too high a volume or concentration,
or if it is injected too fast, DMSO is potentially toxic to
blood vessels and may lead to acute vessel damage,
vasospasm, endothelial necrosis and severe inflammatory
response in the arterial wall [3]. Dudeck et al. [4] report
that DMSO induced the most pronounced vasospasm
with the longest recovery period of all solvents investi-
gated. The systemic side effects of DMSO vary from
bronchospasm and pulmonary oedema to vasospasm and
cardiac arrest [3,5]. Systemic toxicity, resulting in cardiac
complications, has therefore been a major concern
[2,6].
Previous studies had focused on comparing the effects of
different solvents on BP, HR and ECG without, however,
commenting on Onyx injection and SpO2 [4]. Pamuk et al.
[7] demonstrated oxygen desaturation in the postopera-
tive period for patients undergoing embolization of
aneurysms using a combination of Onyx and stainless-
steel stents. In the embolization of AVMs, not only is the
percentage of DMSO higher than that used for aneur-
ysms but also larger volumes are given with repeated
injections of DMSO; this may result in a potentially
higher risk of complications.
In our case series, desaturation was an event with more
than one possible explanation. It can be attributed to a
reduction in vital lung capacity after injection of DMSO.
For instance, the patient with severe desaturation was
unable to achieve maximal expiration and increase the
inspiratory volume capacity over the tidal volume (rest-
ing) when she was prompted to do so. There was no
evidence of atelectasia due to anaesthetic agents, so one
can hypothesize that the vital capacity was affected by
the injection of DMSO. Prospective studies on pulmon-
ary function in these cases should help clarify the mech-
anism of hypoxaemia.
Although it is known that most of the DMSO metabolites
are eliminated through the kidneys, some of the early
elimination occurs via the skin and lungs. Dilution of
oxygen in the lungs may cause a relative decrease in the
partial pressure of oxygen in the alveoli. Desaturation
cannot be attributed to the use of dyes such as methyleneuthorized reproduction of this article is prohibited.
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Fig. 1
The Reynolds approach to lightwand intubation.blue and indocyanine green as these agents are not
routinely used during embolizations.
The patient with severe desaturation of SpO2 after extu-
bation did not experience any respiratory distress or
hypotension, and the PaO2–FiO2 was more than 200, so
the possibility of pulmonary oedema and acute respirat-
ory distress syndrome could not be established. Intrao-
perative embolism by air or Onyx is unlikely because
patients did not present with tachycardia, systemic hypo-
tension or cardiac arrhythmia in the intraoperative and
postoperative period, and, also, the EtCO2 did not change
in any of the patients.
Therefore, a larger prospective randomized study is
needed to confirm our observation and explain its cause.
Such a study should also include a longer follow-up
period of oxygen monitoring.
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Editor,
The use of the lightwand for endotracheal intubation has
been demonstrated to be a useful technique, particularlyright © European Society of Anaesthesiology. Unafter failed laryngoscopy [1]. It is included in the
American Society of Anesthesiologists’ difficult airway
algorithm as well [2]. Moreover, Friedman et al. [3] noted
that patients had less dysphagia, dysarthria and a lower
severity of sore throat with lightwand intubation than
with standard laryngoscopy.
With the traditional teaching for lightwand intubation,
the clinician holds the wand similar to a pencil, stands
directly behind the patient’s head, inserts the device into
the side of the mouth and sweeps the tip to the midline
[4]. Our teaching varies considerably from this approach
and allows all providers to safely and quickly per-
form lightwand intubations, regardless of their level of
experience.
The key aspect of our approach involves having the
clinician stand to the left of the patient’s head instead
of the traditional intubating position. This stance pro-
vides numerous advantages. First, it gives the clinician
a better view of the anterior neck by placing one’s
eyes directly above the target – the glottis. Second, it
improves the degree of jaw thrust the clinician is able to
provide with the left hand (thereby lifting the epiglottis
away from the vocal cords). Third, standing to the
patient’s left forces the intubating right arm into a more
rigid, elbow-elevated position. With the elbow elevated,
glottic entry is smoother because it allows the clinician toauthorized reproduction of this article is prohibited.
Copyr
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light into the glottis (Fig. 1). Finally, this position allows
the clinician to slide the endotracheal tube off the
lightwand using the left hand because the right arm is
now rigidly fixed upon entry through the glottis. This
approach has greatly simplified every aspect of the pro-
cedure for us and has shortened its duration to a matter of
seconds, regardless of the clinician’s level of experience.
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